Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS

C9ORF72 Amyotrophic Lateral Sclerosis (ALS) Clinical Trial

Official title:

Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02686268
• Other study ID #: 14LGCA123
• Status: Completed
• Start date: February 2015
• Est. completion date: October 2, 2018

Study information

• Verified date: July 2021
• Source: Washington University School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This research study is being performed to better understand a specific form of Amyotrophic Lateral Sclerosis (ALS) caused by a mutation (or abnormality) of the C9ORF72 gene. This mutation is the most common genetic cause of ALS, and is present in 40% of ALS patients with a family history of ALS and 5-10% of ALS patients without a family history of ALS.

Description:

Individuals diagnosed with ALS, who are confirmed to carry the Chromosome 9 Open Reading Frame 72 (C9ORF72) gene mutation by CLIA-certified lab results, are eligible for enrollment. Researchers want to understand the natural history of C9ORF72 related ALS in terms of measures of rate of progression as well as understanding how the size of the hexanucleotide repeat expansion influences disease parameters. The investigators hope that the intense study of patients with the C9ORF72 mutation will ultimately help us develop treatments for this common form of ALS.

Objectives:

• Enroll a total of 120 C9ORF72 ALS participants with known mutation at the time of enrollment.

• Determine the C9ORF72 hexanucleotide repeat expansion size in all subjects

• Define ALS disease course

• Determine to what degree the disease course correlates with expansion size

• Collect biomarker samples (blood, DNA and CSF)

Eligibility:

• Adults over age 18 with known C9ORF72 ALS status

Design:

Participants will have up to 9 in-person visits (this includes two Optional visits for lumbar puncture procedures) and 5 telephone interviews over 3 years. Each in-person visit may be tied to a regular clinic visit if subject is local (except for the optional lumbar puncture visits) or if the subject is from out of town one initial visit can be set up with all other visits performed via a telephone call and medical records review.

At each in town visit, subjects will undergo a blood draw (optional lumbar puncture) and two questionnaires (ALS Functional Rating Scale - revised ALSFRS-R) which measures motor function and the ALS-Cognitive Behavioral Screen (ALS-CBS) which will detect signs of Frontal Temporal Dementia and a breathing test to determine Slow Vital Capacity (SVC) measurements.

For out of town subjects - blood draws can be scheduled locally and sent to the study site for analysis. The ALSFRS-R can be performed over the phone along with other study related questions.

The C9ORF72 mutation is called a "dominant" mutation, which means that their children have a 50% chance of inheriting the gene. Most people who inherit the C9ORF72 mutation will develop either ALS or the related disease called fronto-temporal dementia. However, it may be possible for someone to test positive for the C9ORF72 gene mutation and never develop symptoms. Furthermore, in addition to C9ORF72, there are many other gene mutations that can cause ALS. This study will not test these other genes, and therefore a negative test result for the C9ORF72 mutation will not exclude the possibility that you have a heritable form of ALS.

In order to understand the natural history of C9ORF72 related ALS in terms of measures of rate of progression, the investigators need to understand how the size of the hexanucleotide repeat expansion influences disease parameters. A C9ORF72-focused clinical trial defining an accurate historical control population, will be critical since there may not be enough subjects for a placebo controlled trial. To be ready for upcoming therapeutic trials, the investigators need to start the detailed characterization of the C9ORF72 patients immediately.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 128
• Est. completion date: October 2, 2018
• Est. primary completion date: December 31, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion:

1. Males or females of any race aged 18 or older

2. Known positive C9ORF72 ALS status via CLIA-certified lab results.

3. Capable of providing informed consent and following study procedures. In the event that an individual lacks the ability to provide informed consent, informed consent may be sought from the individual's legal, surrogate representative.

4. Geographically accessible to the site.

Exclusion:

1. Geographically inaccessible to the site

2. C9ORF72 ALS negative via CLIA-certified lab results

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• C9ORF72 Amyotrophic Lateral Sclerosis (ALS)
• Motor Neuron Disease
• Sclerosis

Locations

Country	Name	City	State
Netherlands	UMC Utrecht	Utrecht
United States	University of Massachusetts	Amherst	Massachusetts
United States	Johns Hopkins	Baltimore	Maryland
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	Cedars Sinai Medical Center	Los Angeles	California
United States	Columbia University Medical Center	New York	New York
United States	Washington University in St. Louis	Saint Louis	Missouri
United States	Sentara Health Care / Sentara Neurology Specialists	Virginia Beach	Virginia

Sponsors (9)

Lead Sponsor	Collaborator
Washington University School of Medicine	ALS Association, Biogen, Cedars-Sinai Medical Center, Columbia University, Johns Hopkins University, Massachusetts General Hospital, UMC Utrecht, University of Massachusetts, Amherst

Countries where clinical trial is conducted

United States,  Netherlands, 

References & Publications (1)

Cammack AJ, Atassi N, Hyman T, van den Berg LH, Harms M, Baloh RH, Brown RH, van Es MA, Veldink JH, de Vries BS, Rothstein JD, Drain C, Jockel-Balsarotti J, Malcolm A, Boodram S, Salter A, Wightman N, Yu H, Sherman AV, Esparza TJ, McKenna-Yasek D, Owegi MA, Douthwright C; Alzheimer's Disease Neuroimaging Initiative, McCampbell A, Ferguson T, Cruchaga C, Cudkowicz M, Miller TM. Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers. Neurology. 2019 Oct 22;93(17):e1605-e1617. doi: 10.1212/WNL.0000000000008359. Epub 2019 Oct 2. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Collection of clinical data and biomarker samples	The primary outcome measures will be the collection of clinical data (ALSFRS, ALS-CBS and SVC) to determine rates of disease progression and collection of biomarkers samples (blood, CSF) to be correlated with the clinical measures.	December 2017
Secondary	Correlation of repeat expansion size with clinical outcome measures and determination of C9ORF72 patients eligibility for clinical trials	The secondary outcome measures include determination of the C9ORF72 hexanucleotide repeat expansion size and correlating this with the outcome measures of disease progression collected (ALSFRS-R/month, decrease in SVC/month and ALS Cognitive Screen) and determination of C9ORF72 ALS patients that may be available for a clinical trial.	December 2017